Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Although protease inhibitors can inhibit Akt activation and the proliferation of over 60 cancer cell lines, as well as improve sensitivity to radiation or chemotherapy, these effects do not always correlate with Akt inhibition. Other important processes, such as the induction of endoplasmic reticulum stress, appear critical to the biological activity of protease inhibitors. These impressive and surprising preclinical data have prompted clinical testing of nelfinavir as a lead HIV protease inhibitor in cancer patients. SUMMARY:
|
Authors | Wendy B Bernstein, Phillip A Dennis |
Journal | Current opinion in HIV and AIDS
(Curr Opin HIV AIDS)
Vol. 3
Issue 6
Pg. 666-75
(Nov 2008)
ISSN: 1746-6318 [Electronic] United States |
PMID | 19373040
(Publication Type: Journal Article)
|